apDia > SECU
Secukinumab ELISA (REF. 710701)
The Secukinumab ELISA is an enzyme linked immunosorbent assay intended for the quantitative determination of secukinumab (Cosentyx®) in human serum and plasma.
Therapeutic Drug Monitoring
Secukinumab is a fully human monoclonal antibody that binds to interleukin-17 (IL-17A) to treat moderate to severe plaque psoriasis and psoriatic arthritis.
A drug can only exert its pharmacological effect when adequate concentrations are achieved in the circulation. The serum concentration of biologicals just before the next administration, defined as trough concentration, has been used for therapeutic drug monitoring (TDM). Recent data have shown a positive relationship between secukinumab serum concentration, either measured at trough or at an intermediate time point, and clinical outcomes in patients with plaque psoriasis. TDM may therefore be very instrumental to optimize treatment(1,2).
The Secukinumab ELISA uses highly specific monoclonal antibodies developed at the University of Leuven, Belgium (KU Leuven). Anti-TNF drugs (like infliximab, adalimumab, golimumab) or anti-integrin α4β7 drugs (like vedolizumab) do not interfere with the measurement.
As an example of TDM, the use of secukinumab concentration measurements in plaque psoriasis is described.
Plaque psoriasis
Secukinumab (300 mg) is administered subcutaneously at weeks 0, 1, 2, 3, and 4 in the induction phase and thereafter 300 mg every 4 weeks. Treatment with secukinumab results in rapid and significant improvements in patients with moderate-to-severe psoriasis whereby TDM has been proven to be a valuable tool in treatment management. In the BIOLOPTIM-SEC study, a steady-state target concentration of 39.1 µg/ml has been determined. The upper limit trough concentration at steady state, when optimal response was defined by PASI ≤ 2, has been identified at 45.2 µg/ml; when optimal response was defined by PASI90, the upper limit trough concentration was determined at 62.9 µg/ml(2).
Immunogenicity
The incidence of developing anti-secukinumab antibodies is low (0.3% – 0.4%)(3,4).
References:
(1) Speeckaert R, van Geel N, Lambert J, Claeys L, Delanghe JR, Speeckaert MM. Secukinumab: IL-17A inhibition to treat psoriatic arthritis. Drugs Today (Barc). 2016 Nov;52(11):607-616.
(2) Soenen R, Wang Z, Grine L, Dreesen E, Schots L, Brouwers E, Declerck P, Thomas D, Lambert J. Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis. Clin Exp Dermatol. 2022 Jul;47(7):1324-1336.
(3) Liau MM, Oon HH. Therapeutic drug monitoring of biologics in psoriasis. Biologics. 2019 Jul 5;13:127-132.
(4) Reich K, Körber A, Mrowietz U, Sticherling M, Sieder C, Früh J, Bachhuber T. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol. 2021 May;184(5):849-856.
WHY CHOOSE FOR
SECUKINUMAB KIT 96 TESTS, REF. 710701
The ELISA kits offered by apDia are validated on open ELISA automates such as the Dynex Instruments.
instructions for use (IFU) available upon request
DIRECT CONTACT
ORDER NOW
- Call or mail us now.
- You get in touch directly with your contact person.
- You get a concrete answer for the next step.
